Zim Laboratories Limited has informed the Exchange about Transcript
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories reported Q1 FY'26 revenue of INR718 million, down 12.3% year-on-year, impacted by Middle East geopolitical disruptions (airspace closures, supply delays) and softer innovation-led product orders. The company swung to a net loss of INR19 million versus a profit of INR9 million in Q1 FY'25, while EBITDA fell 36.7% to INR57 million (7.9% margin) due to operating deleverage and higher depreciation and finance costs. An EU-GMP inspection concluded with 2 critical and several major observations, all related to manual documentation systems rather than product quality, with a CAPA plan to be submitted by August 31, 2025 and full resolution expected in 6-9 months. The innovation pipeline remains strong with 12 NIP products in development (8 filed in EU), TGA Australia approval for Tamsulosin + Dutasteride, Neuraxpharm partnership launches expected in H2 FY'26, and a UAE Global Pharma partnership with 5 products filed and first orders received.
Near-term stock sentiment may remain subdued due to the EU-GMP setback pushing back product launches by 3-9 months and continued Middle East volatility (~30% of revenue). However, management expects normalization within 2 quarters, and the deep pipeline, licensing income growth (INR40 million from NIP licensing), and partner traction provide medium-term growth visibility for patient shareholders.